Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Rituximab in Progressive Multiple Sclerosis
2014-005493-11Phase 2Completed
- Sponsor
- Centre Hospitalier de Pau
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in multiple sclerosis (MS), sponsored by Centre Hospitalier de Pau. Primary endpoint: Osteopontin level in CSF at day 4. Started Mar 2018; status: completed.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-005493-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005493-11.